Dexxon Holdings Ltd.'s Form 4 filing
Roivant Sciences Ltd. (ROIV) · filed Nov 14, 2022
- Accession no.
- 0001104659-22-117847
- Filed
- Nov 14, 2022, 8:40 AM ET
- Trade date
- Nov 10, 2022
- Filing delay
- 4 days
- Rule 10b5-1 plan
- Not on the form (before 2023)
This filing lists 1 non-derivative transaction. Open-market purchases total $20.0M. It was filed 4 days after the trade.
Reporting owners
A Form 4 can have several reporting owners, such as a person and a fund they control. Trade tables show the first one.
| Owner | Relationship to the company |
|---|---|
| Dexxon Holdings Ltd.CIK 0001636684 | 10% Owner |
| Oren DanCIK 0001636701 | 10% Owner |
| Dexcel Pharma Technologies Ltd.CIK 0001720007 | 10% Owner |
Non-derivative securities (Table I)
Acquisitions and disposals of common stock and similar shares, one row per line on the filing.
| Trade date | Security | Transaction | Shares | Price | Value | Shares after | Ownership | Flags |
|---|---|---|---|---|---|---|---|---|
| Nov 10, 2022 | Common Shares | PPurchaseAcquired | +4,000,000 | $5.00F2 | +$20,000,000 | 102,849,443 | Direct |
Footnotes and remarks
Livermore keeps the footnotes that transaction prices refer to, all footnotes of amendments (Form 4/A) and the filing's remarks. Other footnotes, such as how indirect holdings are held or the details of a trading plan, are only in the original on SEC EDGAR.
- F2
The common shares were purchased by Dexcel in a registered public offering on November 10, 2022.
Referenced by the price of 1 transaction in Table I.